Organon & Co. (OGN)

USD 9.59

(1.48%)

Long Term Debt Summary of Organon & Co.

  • Organon & Co.'s latest annual long term debt in 2023 was 8.75 Billion USD , down -1.73% from previous year.
  • Organon & Co.'s latest quarterly long term debt in 2024 Q2 was 8.64 Billion USD , down -0.67% from previous quarter.
  • Organon & Co. reported annual long term debt of 8.9 Billion USD in 2022, down -2.41% from previous year.
  • Organon & Co. reported annual long term debt of 9.12 Billion USD in 2021, up 39573.91% from previous year.
  • Organon & Co. reported quarterly long term debt of 8.73 Million USD for 2024 Q3, up 1.06% from previous quarter.
  • Organon & Co. reported quarterly long term debt of 8.64 Billion USD for 2024 Q2, down -0.67% from previous quarter.

Annual Long Term Debt Chart of Organon & Co. (2023 - 2018)

Historical Annual Long Term Debt of Organon & Co. (2023 - 2018)

Year Long Term Debt Long Term Debt Growth
2023 8.75 Billion USD -1.73%
2022 8.9 Billion USD -2.41%
2021 9.12 Billion USD 39573.91%
2020 23 Million USD -67.14%
2019 70 Million USD 105.88%
2018 34 Million USD 0.0%

Peer Long Term Debt Comparison of Organon & Co.

Name Long Term Debt Long Term Debt Difference
AbbVie Inc. 52.19 Billion USD 83.234%
Bristol-Myers Squibb Company 38.18 Billion USD 77.081%
Bristol-Myers Squibb Company Ce 38.18 Billion USD 77.081%
Johnson & Johnson 25.88 Billion USD 66.188%
Eli Lilly and Company 18.32 Billion USD 52.235%
Merck & Co., Inc. 33.68 Billion USD 74.02%
Novartis AG 20.03 Billion USD 56.319%
Pfizer Inc. 61.53 Billion USD 85.78%